Forbes reporter Katie Jennings spotlights Phillip (Terry) Ragon '72, and his philanthropic efforts focused on curing HIV. “Ragon’s approach has been to bring together scientists who don’t typically collaborate, including doctors, engineers, physicists, mathematicians and virologists,” writes Jennings.
Using an artificial intelligence system, researchers at MIT and elsewhere have developed a new Covid-19 vaccine that could be effective against current and future strains, reports Gwen Egan for Boston.com. “The vaccine differs from others currently on the market due to the portion of the virus being targeted,” writes Egan.
Boston Globe reporter Hiawatha Bray writes that MIT researchers have used an AI system to identify a potential new Covid-19 vaccine that may be effective against both current and future variants of the virus. “The new vaccine targets a portion of the COVID virus that is much less prone to evolve,” writes Bray. “That could potentially make it effective against many different versions of the virus, eliminating the need for routine booster shots.”
MIT researchers have developed a new approach to vaccines that uses “a machine learning twist [that] could put an end to boosters and seasonal variant shots,” reports Devin Coldewey for TechCrunch.
Writing for The Boston Globe, Prof. Linda Griffith underscores the pressing need to invest in studying women’s health and menstruation science. “These were the attitudes society had about breast cancer decades ago; we didn’t talk about it. But then we finally focused on the science, and overcame the squeamishness about mentioning ‘breasts’ by creating a technical language that could be spoken without hesitation by anyone,” writes Griffith. “We need a similar scientific push for menstruation science, and a comfort level with the language that goes with it. It’s time.”
Writing for The Boston Globe, Prof. Edward Scolnick and La Jolla Institute for Immunology Prof. Erica Ollmann Saphire share their insights on the future and potential challenges in developing a universal Covid-19 vaccine. “Success will require two principles that the world has not yet sufficiently grasped in fighting this virus: a focus on the long term over the short term, and a sustainable structure and support for collaboration,” write Scolnick and Saphire.
Nature reporter Eric Bender spotlights MIT startup Kytopen, which has developed a microfluidic platform to create induced pluripotent stem (iPS) cells and other forms of cell therapy. We want to do minimally invasive surgery,” says Kytopen co-founder Prof. Cullen Buie.
Broad Institute postdoctoral associate Joshua Weinstein has developed a DNA microscope that allows researchers to investigate the locations and identity of DNA molecules, reports Sharon Begley for STAT. “Weinstein has so far used it to image human cancer cell lines and plans to apply the technology to tumors and the immune cells that infiltrate them,” writes Begley, “which might one day guide immunotherapy.”
MIT researchers have found that some inactive ingredients in medications could play a role in triggering irritation or allergic reactions, reports Bob McDonald for CBC Radio. The researchers hope that, “pharmaceutical companies provide more information to doctors, and that alternative drug formulas can be developed for people with allergies or sensitivities.”
Prof. Giovanni Traverso speaks with STAT reporter Shraddha Chakradhar about a study examining how the inactive substances in most medications could trigger a patient’s allergies and intolerances. “As you start taking more and more tablets, then you are also taking more and more of some of these ingredients,” says Traverso. “We want to raise awareness that these ingredients are there.”
NBC News reporter Linda Caroll writes about a new study by MIT researchers showing that inactive ingredients in medications could lead to adverse reactions in some patients. The researchers found that some of the inactive ingredients “can worsen symptoms in people with conditions such as irritable bowel syndrome, or IBS.”
Gizmodo reporter Ed Cara writes about a study by MIT researchers have finds “inactive” ingredients in pills could trigger a patient’s allergies or intolerances. “We’re not saying that everyone should stop taking these medications,” explains Prof. Giovanni Traverso. “But people with an allergy or intolerance should definitely have the opportunity to find out if they have to worry about certain medications.”
MIT researchers have found that many pills contain “inactive” ingredients that could be troublesome for patients, reports Richard Harris for NPR. Prof. Giovanni Traverso explains that if a patient with lactose intolerance takes a pill containing lactose, “it's probably not going to manifest in any significant symptoms. But as the number of pills you're taking [increases], then certainly you might cross that threshold."
AP reporter Lauran Neergaard writes that a new study by MIT researchers finds that pills often contain “inactive” ingredients capable of causing allergic or gastrointestinal reactions. The researchers found that “it’s hard for those patients, or even their doctors, to tell if a pill contains an extra ingredient they should avoid,” Neergaard explains.
STAT reporter Orly Nadell Farber writes about a new study by MIT researchers that shows glaucoma might be caused by T-cells, an integral component of the human body’s immune system, attacking retinal cells. Farber explains that, “this discovery could unlock a critical new door for treatment options.”